•
Mar 31

Madrigal Q1 2025 Earnings Report

Madrigal Pharmaceuticals reported first-quarter 2025 financial results with Rezdiffra net sales of $137.3 million.

Key Takeaways

Madrigal Pharmaceuticals reported a net loss of $73.2 million for the first quarter of 2025, driven by increased operating expenses related to the commercial launch of Rezdiffra. Revenue from Rezdiffra net sales was $137.3 million in its first quarter of commercialization. The company ended the quarter with $848.1 million in cash, cash equivalents, restricted cash and marketable securities.

First-quarter 2025 Rezdiffra net sales were $137.3 million.

More than 17,000 patients were on Rezdiffra as of March 31, 2025.

The company had $848.1 million in cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025.

Operating expenses increased significantly year-over-year primarily due to commercial launch activities for Rezdiffra.

Total Revenue
$137M
0
EPS
-$3.32
Previous year: -$7.38
-55.0%
R&D Expense
$44.2M
Previous year: $71.2M
-38.0%
SG&A Expense
$168M
Previous year: $80.8M
+107.8%
Interest Income
$9.37M
Previous year: $8.33M
+12.4%
Gross Profit
$133M
Previous year: -$168K
-79110.1%
Cash and Equivalents
$848M
Previous year: $1.1B
-22.9%
Total Assets
$997M
Previous year: $1.08B
-7.9%

Madrigal

Madrigal

Forward Guidance

Madrigal expects continued strong uptake of Rezdiffra and anticipates sharing further data from clinical trials, including late-breaking F4c data at EASL, and is awaiting a regulatory decision in Europe.

Positive Outlook

  • Rezdiffra is positioned to become a foundational therapy for MASH.
  • Anticipating positive data from MAESTRO-NAFLD-1 trial F4c arm at EASL Congress.
  • Potential for European regulatory approval and launch mid-year.
  • Strong patient adoption with over 17,000 patients on Rezdiffra.
  • Positive feedback received from healthcare providers regarding Rezdiffra's impact on key MASH measures.

Challenges Ahead

  • MAESTRO-NASH OUTCOMES trial data for F4c patients is not anticipated until 2027.
  • Continued operating losses are expected due to commercial launch activities.
  • Regulatory approval in Europe is not guaranteed.
  • Requires sufficient capital to fund ongoing operations.
  • Subject to risks and uncertainties inherent in clinical testing and market acceptance.